MANSCAPED™ Goes Global, Offering Below-The-Waist Grooming Products to 1 Billion Consumers Worldwide
22.10.2020 16:00:00 EEST | Business Wire | Press release
Male grooming. In this day and age, these two words can - and should - mean trimming and tidying up all areas of a man’s body, including the nether regions. You may have thought about it, or even partaken in this all-important activity and reaped the results! But was it as enjoyable as it was effective? And, more importantly, were you equipped with the right tools for the job?
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022005418/en/
The leader in male below-the-waist grooming is now shipping its sought-after collection of precision engineered tools, unique formulations, and accessories to the European Union. (Photo: Business Wire)
If you are not already familiar with the pioneer below-the-waist grooming and hygiene brand, let us formally introduce you to MANSCAPED™. This California-based startup has single-handedly disrupted the men’s grooming industry and created a completely new category in the consumer packaged goods space.
Born in 2016, the booming direct-to-consumer (DTC) company designs and develops premium products for groin and body grooming, while upholding a steadfast mission to empower the modern man to unabashedly grab ahold of his situation “down there”. We are proud to report that since inception, the stigma-shattering brand has utterly taken off.
Today, MANSCAPED announces its latest and most extensive expansion yet into the European Union, which augments its reach to 1 billion people worldwide. This follows successful international launches earlier this year into Canada, Australia, New Zealand, and the United Kingdom. With the holidays on the horizon, the perfect present or self-care treat is now just a click away for every lady and gentleman in more than 30 countries worldwide.
“Entering into Europe in one fell swoop is no small feat, but we’re confident we have the infrastructure and high-powered passion to fuel this momentous launch,” said Stephanie Hinze, MANSCAPED’s Senior Director of International Operations. “Sharing the European Union’s values of inclusion and non-discrimination, we believe our trusted brand and superior products have sparked a new era of well-being for all and will continue to propel a movement throughout the region. We’re particularly excited to have laid the groundwork just in time for the holiday season in order to offer only the best tools and formulations to so many more men and women throughout the world.”
If that news doesn’t excite consumers enough, this milestone is coupled with a new product launch that our international fans have been waiting for. That’s right, our very first above-the-waist tool* is now available in over 30 countries! Combine this groundbreaking device with our best-selling below-the-waist trimmer and skincare products, and you have a set of essentials that is a must-have for the men on your list...
Introducing The Performance Package, our newest luxury grooming kit that includes:
The Lawn Mower™ 3.0 - The legendary electric trimmer for the groin and body is the cornerstone of a refined grooming routine. The precision engineered device boasts a 7,000 RPM motor with QuietStroke™ technology and replaceable ceramic blade with MANSCAPED’s SkinSafe™ technology that helps reduce the risk of nicks, cuts, and snags. The 600mA Li-Ion rechargeable battery and waterproof ergonomic design allows for a safe and easy trimming session.
*The Weed Whacker™ - Now Available Internationally - This revolutionary electric ear and nose hair trimmer is a technological masterpiece, redesigning the traditional nose hair taming tool by focusing on maximum performance and comfort, and offering a sleek, ultramodern design. The tool features SkinSafe technology, a 9,000 RPM motor and 360-degree rotary dual-blade system, and intelligently contoured design.
Crop Preserver™ - Ball deodorant is a thing, and it’s life-changing. The anti-chafing formula is infused with cooling aloe vera and controls any stench coming from an unwanted “swamp crotch”.
Crop Reviver™ - This innovative ball toner is the solution for maintaining hygiene and cleanliness on-the-go. The restorative spray relieves high-friction areas and post-shave irritation with just a spritz or two.
As a leading DTC brand, MANSCAPED offers a one-stop-shop online where customers can browse the full collection and purchase items a la cart or as part of a bundle - all with guaranteed free shipping. For our new consumers residing in Europe, please visit eu.manscaped.com to learn more and join the MANSCAPED Movement today!
About MANSCAPED™:
Founded in 2016, San Diego, California-based MANSCAPED is the global leader in men's grooming and hygiene below-the-waist. The product range includes only the best tools, formulations, and accessories for a simple and effective male grooming routine. MANSCAPED offers direct-to-consumer shipping in more than 30 countries, spanning the United States, Canada, Australia, New Zealand, the United Kingdom, and the European Union. Retail placement includes Target and Best Buy locations throughout the U.S., with further retail availability coming soon. MANSCAPED.com is a one-stop shopping destination for men looking for a brand that is focused on the needs of what has, for too long, been a sensitive and often taboo subject. For more information, visit the website or follow on Facebook, Instagram, Twitter, TikTok, YouTube, and Triller.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005418/en/
Contact information
Allison Frazier, Director of Public Relations – MANSCAPED, Inc.
allison@manscaped.com
925-216-2791
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
